Skip header and navigation

Refine By

6 records – page 1 of 1.

Cost-effectiveness of formoterol and salbutamol as asthma reliever medication in Sweden and in Spain.

https://arctichealth.org/en/permalink/ahliterature9294
Source
Int J Clin Pract. 2005 Jan;59(1):62-8
Publication Type
Article
Date
Jan-2005
Author
B. Lindgren
M R Sears
M. Campbell
C. Villasante
S. Huang
A. Lindh
W. Petermann
K. Svensson
F. Berggren
R A Pauwels
Author Affiliation
Lund University Centre for Health Economics,Lund University, Lund, Sweden. bjorn.lindgren@luche.lu.se
Source
Int J Clin Pract. 2005 Jan;59(1):62-8
Date
Jan-2005
Language
English
Publication Type
Article
Keywords
Administration, Inhalation
Adolescent
Adult
Aged
Aged, 80 and over
Albuterol - economics - therapeutic use
Asthma - drug therapy - economics
Bronchodilator Agents - administration & dosage - economics
Child
Child, Preschool
Comparative Study
Cost-Benefit Analysis
Ethanolamines - administration & dosage - economics
Female
Health Care Costs
Humans
Male
Middle Aged
Nebulizers and Vaporizers
Research Support, Non-U.S. Gov't
Severity of Illness Index
Spain
Sweden
Abstract
This study aimed to evaluate the cost-effectiveness of formoterol (Oxis) Turbuhaler 4.5 microg and salbutamol 200 microg as reliever medications in Sweden and Spain. The study used data on effectiveness (exacerbations and symptom-free days) and resource utilisation from an open, 6-month, parallel-group, multicentre randomised trial with 18,124 asthma patients in 24 countries. Country-specific unit costs for Sweden and for Spain were used to transform resource utilisation data into costs. Total healthcare costs were not significantly different between formoterol and salbutamol dry powder inhalers in Sweden, whereas in Spain, the healthcare costs were 20% higher for formoterol vs. salbutamol pressurised metered dose inhalers. Total healthcare costs increased with disease severity, defined according to the Global Initiative for Asthma guidelines. Compared with salbutamol, formoterol produced statistically significant improvements in effectiveness, less reliever and maintenance medication usage, reduced healthcare resource utilisation, with no increase or a limited increase in healthcare cost.
PubMed ID
15707467 View in PubMed
Less detail

A cost-effectiveness study comparing the as-needed use of formoterol (Oxis) and terbutaline (Bricanyl) in patients with moderate to severe asthma.

https://arctichealth.org/en/permalink/ahliterature10139
Source
Respir Med. 2001 Sep;95(9):753-8
Publication Type
Article
Date
Sep-2001
Author
F. Berggren
T. Ekström
Author Affiliation
AstraZeneca R&D Lund, and Lund University Centre for Health Economics, Sweden. Fredrik.Berggren@astrazeneca.com
Source
Respir Med. 2001 Sep;95(9):753-8
Date
Sep-2001
Language
English
Publication Type
Article
Keywords
Acute Disease
Anti-Asthmatic Agents - administration & dosage - economics
Asthma - drug therapy - economics
Confidence Intervals
Cost Savings
Cost of Illness
Cost-Benefit Analysis
Double-Blind Method
Ethanolamines - administration & dosage - economics
Female
Humans
Male
Middle Aged
Poisson Distribution
Terbutaline - administration & dosage - economics
Treatment Outcome
Abstract
This study evaluated the economic and health-related consequences of the as-needed use of a long-acting beta2-agonist with fast onset (formoterol, Oxis Turbuhaler 4.5 microg) versus a short-acting beta2-agonist (terbutaline, Bricanyl Turbuhaler 0.5 mg) in patients with moderate to severe asthma. A multi-national (Sweden, Norway, The Netherlands and Greece), multi-centre (35 centres), randomized, double-blind clinical trial was conducted using 362 patients on inhaled steroids during a 12-week period. The effectiveness results were pooled and the total costs included estimates for beta2-agonists, inhaled steroids, oral steroids, physician visits and sick-leave. The 182 patients in the formoterol group had 14,404 days of exposure and 29 severe exacerbations, and the 180 patients in the terbutaline group had 13,655 days of exposure and 48 severe exacerbations. The terbutaline group had 62% more severe exacerbations than the formoterol group (P=0.039), based on exposure time. Per patient, the calculated total costs were SEK 3386 for the formoterol group and SEK 3709 for the terbutaline group over the 12-week period. The conclusion is that the use of Oxis Turbuhaler instead of Bricanyl Turbuhaler for as-needed treatment is a more effective treatment generating cost savings from a societal perspective.
PubMed ID
11575897 View in PubMed
Less detail

Lacosamide as treatment of epileptic seizures - cost utility results for Sweden.

https://arctichealth.org/en/permalink/ahliterature145100
Source
Acta Neurol Scand. 2010 Jun;121(6):406-12
Publication Type
Article
Date
Jun-2010
Author
K. Bolin
F. Berggren
L. Forsgren
Author Affiliation
Department of Economics, Lund University, Lund, Sweden. kristian.bolin@nek.lu.se
Source
Acta Neurol Scand. 2010 Jun;121(6):406-12
Date
Jun-2010
Language
English
Publication Type
Article
Keywords
Acetamides - economics - therapeutic use
Anticonvulsants - economics - therapeutic use
Cost-Benefit Analysis
Epilepsy - drug therapy - economics
Follow-Up Studies
Humans
Quality-Adjusted Life Years
Retrospective Studies
Sensitivity and specificity
Sweden - epidemiology
Treatment Outcome
Abstract
To calculate cost per additional quality-adjusted life-year (QALY) for lacosamide as adjunctive treatment for patients with uncontrolled partial-onset seizures as compared to no adjunctive treatment.
A decision-tree simulation model was constructed to calculate the number of seizures and health-care utilization for treated and untreated with lacosamide, respectively. Prices from 2007 were used for all costs.
All results were calculated for a 24-, 18-, 12- and 6-months follow-up. The cost per additional QALY was estimated to euro 27,641 (24 months). Using a willingness-to-pay threshold for a QALY of euro 50,000 the net marginal value of using lacosamide was estimated to about euro 850,000 per 1000 patients.
The estimated cost per QALY gained falls within the range of reported estimates of the willingness-to-pay for an additional QALY. The results imply that lacosamide is cost-effective in the treatment of uncontrolled partial-onset seizures (1 euro approximately 9.6 SEK).
PubMed ID
20199516 View in PubMed
Less detail

Patterns of antiepileptic drug prescription in Sweden: A register-based approach.

https://arctichealth.org/en/permalink/ahliterature291612
Source
Acta Neurol Scand. 2017 Nov; 136(5):521-527
Publication Type
Journal Article
Date
Nov-2017
Author
K Bolin
F Berggren
P Berling
S Morberg
H Gauffin
A-M Landtblom
Author Affiliation
Department of Economics, University of Gothenburg, Gothenburg, Sweden.
Source
Acta Neurol Scand. 2017 Nov; 136(5):521-527
Date
Nov-2017
Language
English
Publication Type
Journal Article
Keywords
Adult
Aged
Anticonvulsants - administration & dosage - therapeutic use
Carbamazepine - administration & dosage - therapeutic use
Drug Prescriptions - statistics & numerical data
Epilepsy - drug therapy
Female
Humans
Male
Middle Aged
Registries
Sweden
Triazines - administration & dosage - therapeutic use
Valproic Acid - administration & dosage - therapeutic use
Abstract
To determine drug utilization pathways from the incident healthcare visit due to epilepsy and three years onward.
Anti-epileptic drug utilization was calculated using individual information on inpatient- and outpatient care utilization and drug sales. Throughout, we used national register information pertaining to pharmaceutical sales linked to diagnosis-related healthcare utilization. Information on pharmaceutical sales was collected for the 2007-2013 period.
For the entire studied period, a majority of new patients with epilepsy were initiated on anti-epileptic drug treatment with a monotherapy (98%); most of these patients remained on that first treatment (64%). The three most frequently prescribed drugs accounted for 72% of the initiated AED treatments. Patients with epilepsy (ICD-10: G40/41) were most commonly prescribed carbamazepine, lamotrigine and valproate. The most common second-line monotherapy was levetiracetam. About 12% of new patients with epilepsy who were initiated on AED treatment during the period eventually switched to an add-on therapy. The proportion of patients who were initiated on treatment with carbamazepine or valproate decreased, and the proportion of patients who remained on their initial monotherapy increased between 2007 and 2013.
A limited number of anti-epileptic drugs accounted for the treatment of a majority of new patients with epilepsy (carbamazepine, lamotrigine and valproate accounted for more than 70%). Add-on therapies showed the same pattern, as the most frequently prescribed add-on regimens were the same ones that accounted for most of the monotherapies. There was a tendency towards fewer patients being initiated on AED treatment with either carbamazepine or valproate.
PubMed ID
28585316 View in PubMed
Less detail

Prevalence and cost of epilepsy in Sweden--a register-based approach.

https://arctichealth.org/en/permalink/ahliterature263823
Source
Acta Neurol Scand. 2015 Jan;131(1):37-44
Publication Type
Article
Date
Jan-2015
Author
K. Bolin
F. Berggren
A-M Landtblom
Source
Acta Neurol Scand. 2015 Jan;131(1):37-44
Date
Jan-2015
Language
English
Publication Type
Article
Keywords
Adult
Ambulatory Care - economics
Cost-Benefit Analysis
Delivery of Health Care - economics
Epilepsy - economics - epidemiology
Female
Health Care Costs - statistics & numerical data
Hospitalization - economics
Humans
Prevalence
Registries
Sweden - epidemiology
Abstract
To estimate the prevalence of epilepsy, costs associated with in- and outpatient care, drug utilization and productivity losses due to epilepsy in Sweden for the years 2005 and 2011.
Cost components were calculated using registry data on inpatient- and outpatient-care utilization, drug sales and early pensions granted due to permanent disability and mortality. Moreover, by cross-identification of information in healthcare and pharmaceutical registries, we were able to distinguish between pharmaceuticals prescribed for epilepsy and non-epilepsy indications.
The prevalence of epilepsy was estimated at 0.62% in 2005 and 0.88% in 2011. The total cost of epilepsy increased during the same period, while the per-patient cost decreased from €2929 to €1729. Direct medical costs accounted for about 36% of the estimated total cost in 2005 and 60% in 2011. The estimated healthcare cost due to epilepsy as a share of total healthcare costs for all illnesses was about the same in 2005 as in 2011 (0.2%), while the corresponding pharmaceutical cost increased from about 0.5% in 2005 to almost 1% in 2011.
The per-patient cost of epilepsy is substantial, implying a significant aggregated cost incurred on society (despite a prevalence
PubMed ID
25195857 View in PubMed
Less detail

Regional variation in prevalence and healthcare utilization due to epilepsy in Sweden.

https://arctichealth.org/en/permalink/ahliterature264689
Source
Acta Neurol Scand. 2014 Dec;130(6):354-9
Publication Type
Article
Date
Dec-2014
Author
K. Bolin
F. Berggren
A-M Landtblom
Source
Acta Neurol Scand. 2014 Dec;130(6):354-9
Date
Dec-2014
Language
English
Publication Type
Article
Keywords
Ambulatory Care - economics
Cost of Illness
Epilepsy - economics - epidemiology
Female
Hospitalization - economics
Humans
Male
Prevalence
Registries
Sweden - epidemiology
Abstract
To estimate the regional differences in the prevalence of epilepsy and the associated costs due to inpatient and outpatient care and anti-epileptic drug (AED) utilization for the years 2005 and 2011 in Sweden.
Region-specific estimates of the prevalence of epilepsy were obtained using a method based on a linkage of the healthcare and pharmaceutical registries and the cause of death registry. Regional cost components were estimated using registry data by region on inpatient and outpatient care utilization, AED sales, and mortality. Per-patient utilization and monetary costs were calculated.
Estimated prevalence of epilepsy varied substantially across the regions in 2011, from 0.76% in Jämtland to 1.08% in Gotland. The national prevalence was 0.88%. The average number of hospitalizations per patient and year decreased at the national level between 2005 and 2011. At the national level, the per-patient specialized care (outpatient) utilization also decreased between 2005 and 2011. However, at the regional level, the decrease was not uniform, and in some counties, the per-patient utilization increased during the period studied. The per-patient utilization of AEDs increased in all counties, except Kronoberg, between 2005 and 2011. Moreover, between-region differences in healthcare and AED utilization, and significant differences between regions and national averages were revealed. Similarly, regional per-patient costs were shown to deviate from the national average in 13 of 21 regions.
There is significant variation in the prevalence of epilepsy and the provision of health care for patients with epilepsy across the different regions of Sweden.
PubMed ID
25040145 View in PubMed
Less detail

6 records – page 1 of 1.